Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsunori Shimoi

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 23, 2023
[Future Prospects for Treatment of Oligometastatic Breast Cancer and Prostate Cancer]Tatsunori Shimoi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
[The Prospective Trial of Patient-Proposed Healthcare Services with Multiple Molecular Targeted Therapy Based on the Result of Comprehensive Genomic Profiling]Tatsunori Shimoi
Medical Oncology (Northwood, London, England)|March 17, 2025
Diagnosis and treatment of cardiac tumorsToru Imai, Tatsunori Shimoi, Akira Kawai, et al.
Future Oncology (London, England)|September 15, 2025
Real-world treatment outcomes of abemaciclib in older patients with HR+, HER2- metastatic breast cancer in JapanTatsunori Shimoi, Yoshinori Tanizawa, Long Jin, et al.
Breast Cancer (Tokyo, Japan)|February 12, 2020
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysisTatsunori Shimoi, Yasuaki Sagara, Fumikata Hara, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Endocrine Therapy for Endometrial Carcinoma: Current Evidence, Resistance Mechanisms, and Biomarker-Driven Patient SelectionTaro Yamanaka, Hiroshi Yoshida, Tatsunori Shimoi, et al.
IJU Case Reports|September 3, 2024
Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutationHiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, et al.
Asian Pacific Journal of Allergy and Immunology|April 25, 2012
Clinical and pathological features of Churg Strauss syndrome among a Japanese population: a case series of 18 patientsTatsunori Shimoi, Kensaku Shojima, Atsuko Murota, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 25, 2025
Oncologists' Views and Communication Practices Regarding Unproven High-Cost Cancer Interventions in Private Medical Practice: A Questionnaire SurveyTsunakuni Ikka, Taichi Hatta, Noriyuki Katsumata, et al.
BMJ Case Reports|April 22, 2025
Double heterozygosity for <i>BRCA1</i> and <i>BRCA2</i> in breast cancer: considerations in surveillance and cancer risk managementNonoko Wakaki, Tatsunori Shimoi, Shogo Nakamoto, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 23, 2023
[Future Prospects for Treatment of Oligometastatic Breast Cancer and Prostate Cancer]Tatsunori Shimoi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
[The Prospective Trial of Patient-Proposed Healthcare Services with Multiple Molecular Targeted Therapy Based on the Result of Comprehensive Genomic Profiling]Tatsunori Shimoi
Medical Oncology (Northwood, London, England)|March 17, 2025
Diagnosis and treatment of cardiac tumorsToru Imai, Tatsunori Shimoi, Akira Kawai, et al.
Future Oncology (London, England)|September 15, 2025
Real-world treatment outcomes of abemaciclib in older patients with HR+, HER2- metastatic breast cancer in JapanTatsunori Shimoi, Yoshinori Tanizawa, Long Jin, et al.
Breast Cancer (Tokyo, Japan)|February 12, 2020
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysisTatsunori Shimoi, Yasuaki Sagara, Fumikata Hara, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Endocrine Therapy for Endometrial Carcinoma: Current Evidence, Resistance Mechanisms, and Biomarker-Driven Patient SelectionTaro Yamanaka, Hiroshi Yoshida, Tatsunori Shimoi, et al.
IJU Case Reports|September 3, 2024
Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutationHiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, et al.
Asian Pacific Journal of Allergy and Immunology|April 25, 2012
Clinical and pathological features of Churg Strauss syndrome among a Japanese population: a case series of 18 patientsTatsunori Shimoi, Kensaku Shojima, Atsuko Murota, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 25, 2025
Oncologists' Views and Communication Practices Regarding Unproven High-Cost Cancer Interventions in Private Medical Practice: A Questionnaire SurveyTsunakuni Ikka, Taichi Hatta, Noriyuki Katsumata, et al.
BMJ Case Reports|April 22, 2025
Double heterozygosity for <i>BRCA1</i> and <i>BRCA2</i> in breast cancer: considerations in surveillance and cancer risk managementNonoko Wakaki, Tatsunori Shimoi, Shogo Nakamoto, et al.
Pageof 12